ES2759605T8 - Formulaciones de 2-iminobiotina y usos de las mismas - Google Patents

Formulaciones de 2-iminobiotina y usos de las mismas

Info

Publication number
ES2759605T8
ES2759605T8 ES11723744T ES11723744T ES2759605T8 ES 2759605 T8 ES2759605 T8 ES 2759605T8 ES 11723744 T ES11723744 T ES 11723744T ES 11723744 T ES11723744 T ES 11723744T ES 2759605 T8 ES2759605 T8 ES 2759605T8
Authority
ES
Spain
Prior art keywords
iminobiotin
formulations
iminobiotin formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11723744T
Other languages
English (en)
Other versions
ES2759605T3 (es
Inventor
Paul Willem Theresia Josef Leufkens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurophyxia BV
Original Assignee
Neurophyxia BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurophyxia BV filed Critical Neurophyxia BV
Application granted granted Critical
Publication of ES2759605T3 publication Critical patent/ES2759605T3/es
Publication of ES2759605T8 publication Critical patent/ES2759605T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
ES11723744T 2010-05-26 2011-05-26 Formulaciones de 2-iminobiotina y usos de las mismas Active ES2759605T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10163925 2010-05-26
PCT/NL2011/050366 WO2011149349A1 (en) 2010-05-26 2011-05-26 2-iminobiotin formulations and uses thereof

Publications (2)

Publication Number Publication Date
ES2759605T3 ES2759605T3 (es) 2020-05-11
ES2759605T8 true ES2759605T8 (es) 2020-05-20

Family

ID=42655614

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11723744T Active ES2759605T3 (es) 2010-05-26 2011-05-26 Formulaciones de 2-iminobiotina y usos de las mismas

Country Status (15)

Country Link
US (2) US9023878B2 (es)
EP (1) EP2575892B1 (es)
JP (1) JP5798621B2 (es)
KR (1) KR101805950B1 (es)
CN (1) CN103037904B (es)
AU (1) AU2011258964B2 (es)
BR (1) BR112012030014B1 (es)
CA (1) CA2837129C (es)
ES (1) ES2759605T3 (es)
HK (1) HK1183448A1 (es)
IL (1) IL223269A (es)
MX (1) MX338405B (es)
NZ (1) NZ604498A (es)
RU (1) RU2627460C2 (es)
WO (1) WO2011149349A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
AU2011258964B2 (en) 2010-05-26 2015-04-16 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof
AU2016372396B2 (en) 2015-12-16 2022-04-14 Neurophyxia B.V. 2-iminobiotin for use in the treatment of brain cell injury
US10463699B2 (en) 2016-04-04 2019-11-05 Omeza LLC Fish oil topical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ATE177078T1 (de) * 1993-10-21 1999-03-15 Searle & Co Amidino-derivate als no-synthetase inhibitoren
RU2230062C2 (ru) 1999-01-21 2004-06-10 Бристол-Маерс Сквибб Ко. Комплекс ингибитора ras-фарнезилтрансферазы, композиция ингибитора ras-фарнезилтрансферазы, фармацевтическая композиция
AU777022B2 (en) * 2000-03-31 2004-09-30 Neurophyxia B.V. Composition for the prevention and/or treatment, in newborn babies, of the effects of complications during childbirth
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
WO2007035760A1 (en) * 2005-09-20 2007-03-29 Board Of Regents, The University Of Texas System Enhanced solubility of preformed calcium citrate by adding citric acid
AU2007304588A1 (en) 2006-10-04 2008-04-10 Neurokey A/S Use of hypothermia inducing drugs to treat ischemia
AU2011258964B2 (en) * 2010-05-26 2015-04-16 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof

Also Published As

Publication number Publication date
AU2011258964A1 (en) 2013-01-17
RU2013152229A (ru) 2015-06-27
HK1183448A1 (en) 2013-12-27
IL223269A (en) 2016-11-30
WO2011149349A1 (en) 2011-12-01
CA2837129A1 (en) 2011-12-01
EP2575892B1 (en) 2019-11-20
BR112012030014B1 (pt) 2021-07-13
AU2011258964B2 (en) 2015-04-16
US9023878B2 (en) 2015-05-05
ES2759605T3 (es) 2020-05-11
CN103037904A (zh) 2013-04-10
EP2575892A1 (en) 2013-04-10
JP2013527200A (ja) 2013-06-27
KR20130117659A (ko) 2013-10-28
BR112012030014A2 (pt) 2016-08-02
CA2837129C (en) 2018-07-03
RU2627460C2 (ru) 2017-08-08
US9616135B2 (en) 2017-04-11
MX2012013695A (es) 2013-02-26
KR101805950B1 (ko) 2017-12-07
IL223269A0 (en) 2013-02-03
MX338405B (es) 2016-04-14
NZ604498A (en) 2014-10-31
JP5798621B2 (ja) 2015-10-21
CN103037904B (zh) 2015-04-22
US20150202303A1 (en) 2015-07-23
US20130143936A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
CL2016000981A1 (es) Formulaciones de estrigolactona y sus usos
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CO7030961A2 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
BR112015006198A2 (pt) conjunto de cadeira
CO6950485A2 (es) Composiciones perfumantes y usos de las mismas
BR112015003838A2 (pt) formulações de anticorpo e proteína
BR112015003125A2 (pt) ingrediente hidrante cosmético ou7 farmacêutico
DK3170508T3 (da) Vaccineformuleringer
CO6950484A2 (es) Composiciones perfumantes y usos de las mismas
IL263978B (en) Amorphous latrovir and solid pharmaceutical preparations containing it and its uses
CO6801713A2 (es) Heteroarilos y sus usos
GT201200303A (es) Formulaciones farmacéuticas
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
BR112014009033A2 (pt) formulações de polímero acrílico
CO6870031A2 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
BR112013023743A2 (pt) anticorpo de fator de tecidos humanos e usos do mesmo
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
BR112015007861A2 (pt) prótese de tecido
CO6940426A2 (es) Formulaciones farmacéuticas
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
BR112014005254A2 (pt) composições antimicrobianas e usos das mesmas
CO6801701A2 (es) Composiciones activas de antitranspirante y fabricación de las mismas
CO6862154A2 (es) Metabolitos de trans-clomifeno y usos de los mismos
IT1400392B1 (it) Dispositivo di protezione delle vertebre cervicali